Showing results (941-950 of 9,976) with videos related to
Sort By:
Pageof 998
Leukemia & Lymphoma|October 14, 2016
Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphomaJoy Benadiba, Celia Rosilio, Marielle Nebout, et al.Leukemia & Lymphoma|October 14, 2016
Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacyJasmin Stettler, Urban Novak, Gabriela M Baerlocher, et al.Leukemia & Lymphoma|September 30, 2016
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximabTomoko Yasuhiro, Wako Sawada, Christian Klein, et al.Leukemia & Lymphoma|October 1, 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasoneElisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, et al.Leukemia & Lymphoma|February 11, 2017
Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphomaOkan Falay, Erman Öztürk, Yasemin Bölükbaşı, et al.Leukemia & Lymphoma|February 1, 2017
Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicinYu-Chien Chang, Wen-Jyi Lo, Yu-Ting Huang, et al.Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.Leukemia & Lymphoma|August 15, 2003
Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myelomaA D Wechalekar, C I Chen, D Sutton, et al.Leukemia & Lymphoma|August 15, 2003
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacyE Jantunen, T Kuittinen, T NousiainenLeukemia & Lymphoma|August 15, 2003
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)Francis J Giles, Carole B Miller, David D Hurd, et al.Pageof 998